Discussion: Due to the presence of mutations, such as L100I, K101P, Y181C, M230L, observed in of individuals failing in the use of EFV, the viability of using ETR in a rescue scheme is reduced for few individuals (data not shown).
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
Result: Four SDRMs increased in prevalence in RTI-naive persons including K103N, V106M, and G190A/E while L100I decreased in prevalence among RTI-naive persons.
Result: Seven SDRMS increased in prevalence among NNRTI-experienced persons including K101E, Y181V, Y188C, G190S, P225H, and M230L while four decreased in prevalence including L100I, V106A, K101P, and V181I.
High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.
Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.
PMID: 33567378
2021
European journal of medicinal chemistry
Abstract: Compounds 16a1 and 16b1 turned out to be the most potent inhibitors against WT and mutant HIV-1 strains (L100I, K103N, and E138K), with EC50 values ranging from 0.007 muM to 0.043 muM.
HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China.
Result: The relatively high resistance to doravirine is noteworthy, and was mainly associated with mutations Y188L (4.5%, in most cases combined with V106I), L100IV (4.5%), K103EP (3.8%), P225H (3.0%).
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Result: Within the NNRTI class, G190 mutations (69.1%, p = 0.015), Y181C (78.6%, p = 0.008), L100I (82.4%, p = 0.019) were significantly more in the TDF/3TC/EFV group whereas mutation K238T (71.4%, p = 0.035) was significantly more in the AZT/3TC/EFV group.
Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.
PMID: 32071061
2020
Antimicrobial agents and chemotherapy
Abstract: Mutations L100I, Y181C, or M230L were present in 27/34 (79%) of samples with an FC of >10 but only in 2/46 (4%) of samples with an FC of <2.9.
Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
HIV mutation literature information.
PMID: 
2021
BioMed research international
Browser Board
Co-occurred Entities
Filtrator
ViMRT